Multi event Drug Recall Enforcement Report Class III voluntary initiated by Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd., originally initiated on 04-09-2024 for the product Abilify (aripiprazole), 5 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC 59148-007-13 The product was recalled due to cross contamination with other products. The product was distributed nationwide and the recall is currently ongoing.
Recall Enforcement Reports
| Recall Number |
Recall Initiation Date |
Report Date |
Recall Classification |
Quantity |
Product Description |
Recall Reason |
Status |
| D-0466-2024 | 04-09-2024 | 05-01-2024 | Class III | 108,192/30 count bottles or 7 count blister packs | Abilify (aripiprazole), 5 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC 59148-007-13 | Cross Contamination with Other Products | Ongoing |
| D-0468-2024 | 04-09-2024 | 05-01-2024 | Class III | N/A | Abilify (aripiprazole), 15 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC 59148-009-13 | Cross Contamination with Other Products | Ongoing |
| D-0467-2024 | 04-09-2024 | 05-01-2024 | Class III | N/A | Abilify (aripiprazole), 10 mg tablets, packaged in a) 30 count bottles (NDC 59148-008-13) and b) 7 count blister packs (NDC 59148-008-95), RX only, Otsuka America Pharmaceutical, Inc. | Cross Contamination with Other Products | Ongoing |
| D-0469-2024 | 04-09-2024 | 05-01-2024 | Class III | N/A | Abilify (aripiprazole), 30 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC 59148-011-13 | Cross Contamination with Other Products | Ongoing |
Recalled Products
